盐酸伊立替康-二氢杨梅素复方脂质体对肝癌细胞的抑制作用  

Inhibition of irinotecan-dihydromyricetin compound liposome on hepatocellular carcinoma cells

作　　者：翟康元 朱艳华[1] 孟莹[1] 韩金津 ZHAI Kang-yuan;ZHU Yan-hua;MENG Ying;HAN Jin-jin(College of Pharmacy,Heilongjiang University of Chinese Medicine,Harbin 150040,China)

机构地区：[1]黑龙江中医药大学药学院

出　　处：《化学工程师》2019年第12期75-79,共5页Chemical Engineer

摘　　要：目的考察盐酸伊立替康(CPT-11)和二氢杨梅素(DMY)联合应用,制备共载化疗药CPT-11及中药成分DMY的复方脂质体,进行体外抗肿瘤实验,以证明盐酸伊立替康-二氢杨梅素复方脂质体联合应用对肝癌HepG2的抑制作用。方法采用MTT法分别探究CPT-11、DMY、CPT-11-DMY及CPT-11-DMY复方脂质体对HepG2细胞的体外抗肿瘤作用。结果确定CPT-11和DMY的质量浓度联用比为1∶4时,二者联用具有协同作用;体外细胞学实验结果表明:复方脂质体能抑制肿瘤HepG2细胞的正常生长,一系列浓度的药物作用于HepG2细胞48h后,复方脂质体的细胞生长的抑制率强于相同浓度下的游离药物。结论在体外抗肿瘤研究中,CPT-11-DMY复方脂质体对肝癌细胞HepG2有明显的抗肿瘤细胞的效果。OBJECTIVE To investigate the combination of irinotecan hydrochloride(CPT-11)and dihydromyricetin(DMY)to prepare compound liposome with CPT-11 and DMY,and to conduct anti-tumor experiments in vitro to prove hydrochloric acid.The inhibitory effect of irinotecan-dihydromyricetin compound liposome on hepatocellular carcinoma HepG2.METHODS The antitumor effects of CPT-11,DMY,CPT-11-DMY and CPT-11-DMY compound liposomes on HepG2 cells were investigated by MTT assay.RESULTS When the mass concentration ratio of CPT-11 and DMY was 1∶4,the combination of the two had synergistic effect.The results of in vitro cytology experiments showed that the compound liposome could inhibit the normal growth of tumor HepG2 cells,a series of concentrations.After 48 hours of treatment with HepG2 cells,the inhibition rate of cell growth of compound liposomes was stronger than that of free drugs at the same concentration.CONCLUSION In vitro anti-tumor studies,CPT-11-DMY compound liposome has obvious anti-tumor effect on HepG2 cells.

关 键 词：二氢杨梅素 盐酸伊立替康 联合应用 复方脂质体 体外抗肿瘤 

分 类 号：R944[医药卫生—药剂学]